Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Collaborations
Science
Science Overview
Synthetic Lethality
Target Discovery
Translational Biology
References
Pipeline
Pipeline Overview
Darovasertib (IDE196)
MAT2A (IDE397)
DLL3 ADC (IDE849)
PARG (IDE161)
Pol Theta (IDE705)
Werner Helicase (IDE275)
Clinical Trials
Clinical Trials Overview
Darovasertib / PKC
IDE397 / MAT2A
IDE161 / PARG
Expanded Access Policy
Contact Us About a Trial
Newsroom
Investors
Investors Overview
News Releases
Events
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Documents & Charters
Board of Directors
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Email Alerts
Careers
Contact
Close Menu
Company
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Collaborations
Science
Science Overview
Synthetic Lethality
Target Discovery
Translational Biology
References
Pipeline
Pipeline Overview
Darovasertib (IDE196)
MAT2A (IDE397)
DLL3 ADC (IDE849)
PARG (IDE161)
Pol Theta (IDE705)
Werner Helicase (IDE275)
Clinical Trials
Clinical Trials Overview
Darovasertib / PKC
IDE397 / MAT2A
IDE161 / PARG
Expanded Access Policy
Contact Us About a Trial
Newsroom
Investors
Investors Overview
News Releases
Events
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Documents & Charters
Board of Directors
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Email Alerts
Careers
Contact
linkedin
rss
email
